$CRVO Balance Sheet | Understand Stock

$CRVO

$2.22 -$0.02 (0.89%) Close

$CRVO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets:
Cash and cash equivalents
Marketable securities
Prepaid expenses, deposits and other current assets
Prepaid expenses and other current assets
Deferred offering costs
Grant receivable
Total current assets
Property and equipment, net
Intangible asset
Right of use asset
Marketable securities, non-current
Other assets
Total assets

Current liabilities:
Accounts payable
Deferred grant revenue
Current operating lease liability
Convertible Notes
Accrued expenses and other current liabilities
Deferred income taxes
Noncurrent operating lease liability
Total liabilities

Stockholders’ Equity:
Convertible preferred stock
Series Preferred Stock
Series A-1 Preferred Stock
Series A-2 Preferred Stock
Series B Preferred Stock
Total convertible preferred stock
Series A preferred stock $0.001 par value: 30,000,000 authorized at March 31, 2026 and December 31, 2025, 0 shares issued and outstanding at March 31, 2026 and December 31, 2025
Series C Preferred Stock
Series A Preferred Stock
Total series A preferred stock $0.001 par value: 30,000,000 authorized at March 31, 2026 and December 31, 2025, 0 shares issued and outstanding at March 31, 2026 and December 31, 2025

Common stock, $0.001 par value: 1,000,000,000 shares authorized at March 31, 2026 and December 31, 2025: 9,258,719 and 9,252,719 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments